

## Complete References

1. Katayanagi T. Nasal methicillin-resistant *S. aureus* is a major risk for mediastinitis in pediatric cardiac surgery. *Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia* 2015;21:37-44.
2. Murray MT, Krishnamurthy G, Corda R, et al. Surgical site infections and bloodstream infections in infants after cardiac surgery. *J Thorac Cardiovasc Surg* 2014;148:259-65.
3. McNeil JC, Ligon JA, Hulten KG, et al. Staphylococcus aureus Infections in Children With Congenital Heart Disease. *J Pediatric Infect Dis Soc* 2013;2:337-44.
4. Lim WH, Lien R, Huang YC, Lee WJ, Lai JY. Community-associated methicillin-resistant Staphylococcus aureus necrotizing pneumonia in a healthy neonate. *J Microbiol Immunol Infect* 2014;47:555-7.
5. Milstone AM, Goldner BW, Ross T, Shepard JW, Carroll KC, Perl TM. Methicillin-Resistant Staphylococcus aureus Colonization and Risk of Subsequent Infection in Critically Ill Children: Importance of Preventing Nosocomial Methicillin-Resistant Staphylococcus aureus Transmission. *Clin Infect Dis* 2011;53:853-9.
6. McNeil JC, Hulten KG, Kaplan SL, Mahoney DH, Mason EO. Staphylococcus aureus infections in pediatric oncology patients: high rates of antimicrobial resistance, antiseptic tolerance and complications. *Pediatr Infect Dis J* 2013;32:124-8.
7. Murray MT, Cohen B, Neu N, et al. Infection prevention and control practices in pediatric long-term care facilities. *Am J Infect Control* 2014;42:1233-4.
8. Dolapo O, Dhanireddy R, Talati AJ. Trends of Staphylococcus aureus bloodstream infections in a neonatal intensive care unit from 2000-2009. *BMC Pediatr* 2014;14:121.
9. Ericson JE, Popoola VO, Smith PB, et al. Burden of Invasive Staphylococcus aureus Infections in Hospitalized Infants. *JAMA Pediatr* 2015;169:1105-11.
10. Cohen-Wolkowicz M, Benjamin DK, Jr., Fowler VG, Jr., et al. Mortality and neurodevelopmental outcome after Staphylococcus aureus bacteremia in infants. *Pediatr Infect Dis J* 2007;26:1159-61.
11. Shane AL, Hansen NI, Stoll BJ, et al. Methicillin-resistant and susceptible Staphylococcus aureus bacteremia and meningitis in preterm infants. *Pediatrics* 2012;129:e914-22.
12. Advani S, Sengupta A, Milstone AM. Postdischarge surveillance to identify subsequent methicillin-resistant Staphylococcus aureus infections in colonized children. *Am J Infect Control* 2013;41:939-41.

13. Rajon K, Vaillancourt R, Varughese N, Villarreal G. Vancomycin use, dosing and serum trough concentrations in the pediatric population: a retrospective institutional review. *Pharmacy practice* 2017;15:887.
14. McNeil JC, Kok EY, Forbes AR, et al. Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome. *Pediatr Infect Dis J* 2016;35:263-8.
15. Le J, Bradley JS, Murray W, et al. Improved vancomycin dosing in children using area under the curve exposure. *Pediatr Infect Dis J* 2013;32:e155-63.
16. Hoang J, Dersch-Mills D, Bresee L, Kraft T, Vanderkooi OG. Achieving therapeutic vancomycin levels in pediatric patients. *The Canadian journal of hospital pharmacy* 2014;67:416-22.
17. Lestner JM, Hill LF, Heath PT, Sharland M. Vancomycin toxicity in neonates: a review of the evidence. *Curr Opin Infect Dis* 2016;29:237-47.
18. Reich PJ, Boyle MG, Hogan PG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus strains in the neonatal intensive care unit: an infection prevention and patient safety challenge. *Clin Microbiol Infect* 2016;22:645 e1-8.
19. Sanchini A, Spitoni MG, Monaco M, et al. Outbreak of skin and soft tissue infections in a hospital newborn nursery in Italy due to community-acquired methicillin-resistant Staphylococcus aureus USA300 clone. *J Hosp Infect* 2013;83:36-40.
20. Newnam KM. Surveillance and Isolation of Methicillin-Resistant Staphylococcus aureus Colonization in the Neonatal Intensive Care Unit. *Adv Neonatal Care* 2016;16:298-307.
21. Nelson MU, Bizzarro MJ, Baltimore RS, Dembry LM, Gallagher PG. Clinical and Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus in a Neonatal Intensive Care Unit in the Decade following Implementation of an Active Detection and Isolation Program. *J Clin Microbiol* 2015;53:2492-501.
22. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. *BMC Infect Dis* 2006;6:130.
23. Desai R, Pannaraj PS, Agopian J, Sugar CA, Liu GY, Miller LG. Survival and transmission of community-associated methicillin-resistant Staphylococcus aureus from fomites. *Am J Infect Control* 2011;39:219-25.
24. Ng W, Faheem A, McGeer A, et al. Community- and Healthcare-Associated Methicillin-Resistant Staphylococcus aureus Strains: An Investigation Into Household Transmission, Risk Factors, and Environmental Contamination. *Infect Control Hosp Epidemiol* 2017;38:61-7.
25. Fritz SA, Hogan PG, Singh LN, et al. Contamination of environmental surfaces with Staphylococcus aureus in households with children infected with methicillin-resistant S aureus. *JAMA Pediatr* 2014;168:1030-8.

26. Bramble M, Morris D, Tolomeo P, Lautenbach E. Potential role of pet animals in household transmission of methicillin-resistant *Staphylococcus aureus*: a narrative review. *Vector borne and zoonotic diseases* (Larchmont, NY) 2011;11:617-20.
27. Morris DO, Lautenbach E, Zaoutis T, Leckerman K, Edelstein PH, Rankin SC. Potential for pet animals to harbour methicillin-resistant *Staphylococcus aureus* when residing with human MRSA patients. *Zoonoses Public Health* 2012;59:286-93.
28. Rodriguez M, Hogan PG, Burnham CA, Fritz SA. Molecular Epidemiology of *Staphylococcus aureus* in Households of Children with Community-Associated *S aureus* Skin and Soft Tissue Infections. *J Pediatr* 2014;164:105-11.
29. Cluzet VC, Gerber JS, Nachamkin I, et al. Risk factors for recurrent colonization with methicillin-resistant *Staphylococcus aureus* in community-dwelling adults and children. *Infect Control Hosp Epidemiol* 2015;36:786-93.
30. Sengupta A, Rand C, Perl TM, Milstone AM. Knowledge, awareness, and attitudes regarding methicillin-resistant *Staphylococcus aureus* among caregivers of hospitalized children. *J Pediatr* 2011;158:416-21.
31. Fritz SA, Krauss MJ, Eplin EK, et al. The natural history of contemporary *Staphylococcus aureus* nasal colonization in community children. *Pediatr Infect Dis J* 2011;30:349-51.
32. Marschall J, Muhlemann K. Duration of methicillin-resistant *Staphylococcus aureus* carriage, according to risk factors for acquisition. *Infect Control Hosp Epidemiol* 2006;27:1206-12.
33. Larsson AK, Gustafsson E, Nilsson AC, Odenholt I, Ringberg H, Melander E. Duration of methicillin-resistant *Staphylococcus aureus* colonization after diagnosis: a four-year experience from southern Sweden. *Scand J Infect Dis* 2011;43:456-62.
34. Cluzet VC, Gerber JS, Nachamkin I, et al. Duration of Colonization and Determinants of Earlier Clearance of Colonization With Methicillin-Resistant *Staphylococcus aureus*. *Clin Infect Dis* 2015;60:1489-96.
35. Popoola VO, Tamma P, Reich NG, Perl TM, Milstone AM. Risk factors for persistent methicillin-resistant *Staphylococcus aureus* colonization in children with multiple intensive care unit admissions. *Infect Control Hosp Epidemiol* 2013;34:748-50.
36. Popoola VO, Carroll KC, Ross T, Reich NG, Perl TM, Milstone AM. Impact of colonization pressure and strain type on methicillin-resistant *Staphylococcus aureus* transmission in children. *Clin Infect Dis* 2013;57:1458-60.
37. Vergnano S. Decolonization and decontamination: what's their role in infection control? *Curr Opin Infect Dis* 2015;28:207-14.

38. Milstone AM, Song X, Coffin S, Elward A. Identification and eradication of methicillin-resistant *Staphylococcus aureus* colonization in the neonatal intensive care unit: results of a national survey. *Infect Control Hosp Epidemiol* 2010;31:766-8.
39. Johnson J, Quach C. Outbreaks in the neonatal ICU: a review of the literature. *Curr Opin Infect Dis* 2017;30:395-403.
40. Huang YC, Lien RI, Lin TY. Effect of mupirocin decolonization on subsequent methicillin-resistant *Staphylococcus aureus* infection in infants in neonatal intensive care units. *Pediatr Infect Dis J* 2015;34:241-5.
41. Huang YC, Lien RI, Su LH, Chou YH, Lin TY. Successful control of methicillin-resistant *Staphylococcus aureus* in endemic neonatal intensive care units--a 7-year campaign. *PLoS One* 2011;6:e23001.
42. Song X, Cheung S, Klontz K, Short B, Campos J, Singh N. A stepwise approach to control an outbreak and ongoing transmission of methicillin-resistant *Staphylococcus aureus* in a neonatal intensive care unit. *Am J Infect Control* 2010;38:607-11.
43. Thorburn K, Taylor N, Saladi SM, van Saene HK. Use of surveillance cultures and enteral vancomycin to control methicillin-resistant *Staphylococcus aureus* in a paediatric intensive care unit. *Clin Microbiol Infect* 2006;12:35-42.
44. Gerber SI, Jones RC, Scott MV, et al. Management of Outbreaks of Methicillin-Resistant *Staphylococcus aureus* Infection in the Neonatal Intensive Care Unit: A Consensus Statement. *Infect Control Hosp Epidemiol* 2006;27:139-45.
45. Scheithauer S, Trepels-Kottek S, Hafner H, et al. Healthcare worker-related MRSA cluster in a German neonatology level III ICU: a true European story. *Int J Hyg Environ Health* 2014;217:307-11.
46. Heinrich N, Mueller A, Bartmann P, Simon A, Bierbaum G, Engelhart S. Successful management of an MRSA outbreak in a neonatal intensive care unit. *Eur J Clin Microbiol Infect Dis* 2011;30:909-13.
47. Lepelletier D, Corvec S, Caillon J, Reynaud A, Roze JC, Gras-Leguen C. Eradication of methicillin-resistant *Staphylococcus aureus* in a neonatal intensive care unit: which measures for which success? *Am J Infect Control* 2009;37:195-200.
48. Delaney HM, Wang E, Melish M. Comprehensive strategy including prophylactic mupirocin to reduce *Staphylococcus aureus* colonization and infection in high-risk neonates. *J Perinatol* 2013;33:313-8.
49. Murillo JL, Cohen M, Kreiswirth B. Results of nasal screening for methicillin-resistant *Staphylococcus aureus* during a neonatal intensive care unit outbreak. *Am J Perinatol* 2010;27:79-81.

50. Pierce R, Bryant K, Elward A, Lessler J, Milstone AM. Bacterial Infections in Neonates Following Mupirocin-Based MRSA Decolonization: A Multicenter Cohort Study. *Infect Control Hosp Epidemiol* 2017;38:930-6.
51. Tamma PD, Aucott SW, Milstone AM. Chlorhexidine use in the neonatal intensive care unit: results from a national survey. *Infect Control Hosp Epidemiol* 2010;31:846-9.
52. Johnson J, Bracken R, Tamma PD, Aucott SW, Bearer C, Milstone AM. Trends in Chlorhexidine Use in US Neonatal Intensive Care Units: Results From a Follow-Up National Survey. *Infect Control Hosp Epidemiol* 2016;in press:1-2.
53. Shah D, Tracy M. Skin antisepsis survey in Australia-New Zealand neonatal nurseries. *J Paediatr Child Health* 2013;49:601-2.
54. Milstone AM, Elward A, Song X, et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. *Lancet* 2013;381:1099-106.
55. Williamson DA, Carter GP, Howden BP. Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns. *Clin Microbiol Rev* 2017;30:827-60.
56. Quach C, Milstone AM, Perpete C, Bonenfant M, Moore DL, Perreault T. Chlorhexidine bathing in a tertiary care neonatal intensive care unit: impact on central line-associated bloodstream infections. *Infect Control Hosp Epidemiol* 2014;35:158-63.
57. Nelson MU, Bizzarro MJ, Dembry LM, Baltimore RS, Gallagher PG. One size does not fit all: why universal decolonization strategies to prevent methicillin-resistant *Staphylococcus aureus* colonization and infection in adult intensive care units may be inappropriate for neonatal intensive care units. *J Perinatol* 2014;34:653-5.
58. Lee A, Harlan R, Breaud AR, et al. Blood concentrations of chlorhexidine in hospitalized children undergoing daily chlorhexidine bathing. *Infect Control Hosp Epidemiol* 2011;32:395-7.
59. Garland JS, Alex CP, Uhing MR, Peterside IE, Rentz A, Harris MC. Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antiseptics for central venous catheter placement in neonates. *J Perinatol* 2009;29:808-13.
60. Ponnusamy V, Venkatesh V, Clarke P. Skin antisepsis in the neonate: what should we use? *Curr Opin Infect Dis* 2014;27:244-50.
61. Aggett PJ, Cooper LV, Ellis SH, McAinsh J. Percutaneous absorption of chlorhexidine in neonatal cord care. *Arch Dis Child* 1981;56:878-80.
62. Chapman AK, Aucott SW, Gilmore MM, Advani S, Clarke W, Milstone AM. Absorption and tolerability of aqueous chlorhexidine gluconate used for skin antisepsis prior to catheter insertion in preterm neonates. *J Perinatol* 2013;33:768-71.

63. Chapman AK, Aucott SW, Milstone AM. Safety of chlorhexidine gluconate used for skin antiseptics in the preterm infant. *J Perinatol* 2012;32:4-9.
64. Lashkari HP, Chow P, Godambe S. Aqueous 2% chlorhexidine-induced chemical burns in an extremely premature infant. *Arch Dis Child Fetal Neonatal Ed* 2012;97:F64.
65. Garland JS, Alex CP, Mueller CD, Cisler-Kahill LA. Local reactions to a chlorhexidine gluconate-impregnated antimicrobial dressing in very low birth weight infants. *Pediatr Infect Dis J* 1996;15:912-4.
66. Garland JS, Alex CP, Mueller CD, et al. A Randomized Trial Comparing Povidone-Iodine to a Chlorhexidine Gluconate-Impregnated Dressing for Prevention of Central Venous Catheter Infections in Neonates. *Pediatrics* 2001;107:1431-6.
67. Sankar MJ, Paul VK, Kapil A, et al. Does skin cleansing with chlorhexidine affect skin condition, temperature and colonization in hospitalized preterm low birth weight infants?: a randomized clinical trial. *J Perinatol* 2009;29:795-801.
68. Sethi K, McKechnie L. PC.28 Changing epidemiology of *Staphylococcus aureus* in neonatal intensive care unit (NICU) at Leeds, 2008-2013. *Arch Dis Child Fetal Neonatal Ed* 2014;99 Suppl 1:A45.
69. Hubner NO, Siebert J, Kramer A. Octenidine dihydrochloride, a modern antiseptic for skin, mucous membranes and wounds. *Skin Pharmacol Physiol* 2010;23:244-58.
70. Harris PN, Le BD, Tambyah P, et al. Antiseptic Body Washes for Reducing the Transmission of Methicillin-Resistant *Staphylococcus aureus*: A Cluster Crossover Study. *Open forum infectious diseases* 2015;2:ofv051.
71. Gastmeier P, Kampf KP, Behnke M, Geffers C, Schwab F. An observational study of the universal use of octenidine to decrease nosocomial bloodstream infections and MDR organisms. *J Antimicrob Chemother* 2016;71:2569-76.
72. Koburger T, Hubner NO, Braun M, Siebert J, Kramer A. Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. *J Antimicrob Chemother* 2010;65:1712-9.
73. Stahl J, Braun M, Siebert J, Kietzmann M. The percutaneous permeation of a combination of 0.1% octenidine dihydrochloride and 2% 2-phenoxyethanol (octenisept(R)) through skin of different species in vitro. *BMC veterinary research* 2011;7:44.
74. Conceicao T, de Lencastre H, Aires-de-Sousa M. Efficacy of octenidine against antibiotic-resistant *Staphylococcus aureus* epidemic clones. *J Antimicrob Chemother* 2016;71:2991-4.
75. Muller G, Langer J, Siebert J, Kramer A. Residual antimicrobial effect of chlorhexidine digluconate and octenidine dihydrochloride on reconstructed human epidermis. *Skin Pharmacol Physiol* 2014;27:1-8.

76. Buehrer C, Bahr S, Siebert J, Wettstein R, Geffers C, Obladen M. Use of 2% 2-phenoxyethanol and 0.1% octenidine as antiseptic in premature newborn infants of 23-26 weeks gestation. *J Hosp Infect* 2002;51:305-7.
77. Kommission für Krankenhaushygiene und Infektionsprävention beim Robert Koch-Institut B. Empfehlung zur Prävention nosokomialer Infektionen bei neonatologischen Intensivpflegepatienten mit einem Geburtsgewicht unter 1500 g. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2007;50:1265-303.
78. Biermann C, Kribs A, Roth B, Tantcheva-Poor I. Use and Cutaneous Side Effects of Skin Antiseptics in Extremely Low Birth Weight Infants - A Retrospective Survey of the German NICUs. *Klin Padiatr* 2016;228:208-212.
79. Landelle C, von Dach E, Haustein T, et al. Randomized, placebo-controlled, double-blind clinical trial to evaluate the efficacy of polyhexanide for topical decolonization of MRSA carriers. *J Antimicrob Chemother* 2016;71:531-8.
80. Kairet K, Ho E, Van Kerkhoven D, et al. USA300, A strain of community-associated methicillin-resistant *Staphylococcus aureus*, crossing Belgium's borders: outbreak of skin and soft tissue infections in a hospital in Belgium. *Eur J Clin Microbiol Infect Dis* 2017;36:905-9.
81. Kampf G, Kramer A. Eradication of methicillin-resistant *Staphylococcus aureus* with an antiseptic soap and nasal mupirocin among colonized patients - an open uncontrolled clinical trial. *Ann Clin Microbiol Antimicrob* 2004;3:9.
82. Popoola VO, Colantuoni E, Suwantararat N, et al. Active Surveillance Cultures and Decolonization to Reduce *Staphylococcus aureus* Infections in the Neonatal Intensive Care Unit. *Infect Control Hosp Epidemiol* 2016;37:381-7.
83. Saiman L. Success of Targeted Strategies to Reduce Methicillin-Susceptible *Staphylococcus aureus* Infections in the Neonatal Intensive Care Unit. *Infect Control Hosp Epidemiol* 2016;37:388-9.
84. Milstone AM, Koontz DW, Voskertchian A, et al. Treating Parents to Reduce NICU Transmission of *Staphylococcus aureus* (TREAT PARENTS) trial: protocol of a multisite randomised, double-blind, placebo-controlled trial. *BMJ open* 2015;5:e009274.
85. Leshem E, Maayan-Metzger A, Rahav G, et al. Transmission of *Staphylococcus aureus* from mothers to newborns. *Pediatr Infect Dis J* 2012;31:360-3.
86. Conceicao T, Aires de Sousa M, Miragaia M, et al. *Staphylococcus aureus* reservoirs and transmission routes in a Portuguese Neonatal Intensive Care Unit: a 30-month surveillance study. *Microb Drug Resist* 2012;18:116-24.

87. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis* 2011;52:e18-55.
88. Creech CB, Beekmann SE, Chen Y, Polgreen PM. Variability among pediatric infectious diseases specialists in the treatment and prevention of methicillin-resistant *Staphylococcus aureus* skin and soft tissue infections. *Pediatr Infect Dis J* 2008;27:270-2.
89. Fritz SA, Camins BC, Eisenstein KA, et al. Effectiveness of measures to eradicate *Staphylococcus aureus* carriage in patients with community-associated skin and soft-tissue infections: a randomized trial. *Infect Control Hosp Epidemiol* 2011;32:872-80.
90. Fritz SA, Hogan PG, Hayek G, et al. Household versus individual approaches to eradication of community-associated *Staphylococcus aureus* in children: a randomized trial. *Clin Infect Dis* 2012;54:743-51.
91. Cluzet VC, Gerber JS, Metlay JP, et al. The Effect of Total Household Decolonization on Clearance of Colonization With Methicillin-Resistant *Staphylococcus aureus*. *Infect Control Hosp Epidemiol* 2016;37:1226-33.
92. Liu AP, Shing MM, Yuen HL, et al. Timing of adjuvant radiotherapy and treatment outcome in childhood ependymoma. *Pediatr Blood Cancer* 2013.
93. Kaplan SL, Forbes A, Hammerman WA, et al. Randomized trial of "bleach baths" plus routine hygienic measures vs. routine hygienic measures alone for prevention of recurrent infections. *Clin Infect Dis* 2014;58:679-82.
94. Tidwell J, Kirk L, Luttrell T, Pike CA. CA-MRSA Decolonization Strategies: Do They Reduce Recurrence Rate? *J Wound Ostomy Continence Nurs* 2016;43:577-82.
95. Baud O, Giron S, Aumeran C, et al. First outbreak of community-acquired MRSA USA300 in France: failure to suppress prolonged MRSA carriage despite decontamination procedures. *Eur J Clin Microbiol Infect Dis* 2014;33:1757-62.
96. Finnell SM, Rosenman MB, Christenson JC, Downs SM. Decolonization of children after incision and drainage for MRSA abscess: a retrospective cohort study. *Clin Pediatr (Phila)* 2015;54:445-50.
97. Jennings JE, Timm NL, Duma EM. Methicillin-resistant *Staphylococcus aureus*: decolonization and prevention prescribing practices for children treated with skin abscesses/boils in a pediatric emergency department. *Pediatr Emerg Care* 2015;31:266-8.
98. Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. *J Antimicrob Chemother* 2015;70:2681-92.



99. Cadilla A, David MZ, Daum RS, Boyle-Vavra S. Association of high-level mupirocin resistance and multidrug-resistant methicillin-resistant *Staphylococcus aureus* at an academic center in the midwestern United States. *J Clin Microbiol* 2011;49:95-100.
100. Batra R, Cooper BS, Whiteley C, Patel AK, Wyncoll D, Edgeworth JD. Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant *Staphylococcus aureus* in an intensive care unit. *Clin Infect Dis* 2010;50:210-7.
101. Meyer B, Cookson B. Does microbial resistance or adaptation to biocides create a hazard in infection prevention and control? *J Hosp Infect* 2010;76:200-5.
102. Kampf G. Acquired resistance to chlorhexidine - is it time to establish an 'antiseptic stewardship' initiative? *J Hosp Infect* 2016;94:213-27.
103. Suwantararat N, Carroll KC, Tekle T, Ross T, Popoola VO, Milstone AM. Low prevalence of mupirocin resistance among hospital-acquired methicillin-resistant *Staphylococcus aureus* isolates in a neonatal intensive care unit with an active surveillance cultures and decolonization program. *Infect Control Hosp Epidemiol* 2015;36:232-4.
104. Schlett CD, Millar EV, Crawford KB, et al. Prevalence of chlorhexidine-resistant methicillin-resistant *Staphylococcus aureus* following prolonged exposure. *Antimicrob Agents Chemother* 2014;58:4404-10.
105. McNeil JC, Kok EY, Vallejo JG, et al. Clinical and Molecular Features of Decreased Chlorhexidine Susceptibility among Nosocomial *Staphylococcus aureus* Isolates at Texas Children's Hospital. *Antimicrob Agents Chemother* 2016;60:1121-8.
106. Antonov NK, Garzon MC, Morel KD, Whittier S, Planet PJ, Lauren CT. High prevalence of mupirocin resistance in *Staphylococcus aureus* isolates from a pediatric population. *Antimicrob Agents Chemother* 2015;59:3350-6.
107. McNeil JC, Hulten KG, Kaplan SL, Mason EO. Mupirocin resistance in *Staphylococcus aureus* causing recurrent skin and soft tissue infections in children. *Antimicrob Agents Chemother* 2011;55:2431-3.
108. Johnson RC, Schlett CD, Crawford K, Lanier JB, Merrell DS, Ellis MW. Recurrent Methicillin-Resistant *Staphylococcus aureus* Cutaneous Abscesses and Selection of Reduced Chlorhexidine Susceptibility during Chlorhexidine Use. *J Clin Microbiol* 2015;53:3677-82.
109. McNeil JC, Hulten KG, Kaplan SL, Mason EO. Decreased susceptibilities to Retapamulin, Mupirocin, and Chlorhexidine among *Staphylococcus aureus* isolates causing skin and soft tissue infections in otherwise healthy children. *Antimicrob Agents Chemother* 2014;58:2878-83.

110. Johnson JG, Saye EJ, Jimenez-Truque N, et al. Frequency of disinfectant resistance genes in pediatric strains of methicillin-resistant *Staphylococcus aureus*. *Infect Control Hosp Epidemiol* 2013;34:1326-7.
111. McClure JA, Zaal DeLongchamp J, Conly JM, Zhang K. Novel Multiplex PCR Assay for Detection of Chlorhexidine-Quaternary Ammonium, Mupirocin, and Methicillin Resistance Genes, with Simultaneous Discrimination of *Staphylococcus aureus* from Coagulase-Negative *Staphylococci*. *J Clin Microbiol* 2017;55:1857-64.
112. Park SH, Kim SY, Lee JH, Park C, Lee DG. Community-genotype strains of methicillin-resistant *Staphylococcus aureus* with high-level mupirocin resistance in a neonatal intensive care unit. *Early Hum Dev* 2013;89:661-5.
113. Guilhermetti M, Hernandez SE, Fukushigue Y, Garcia LB, Cardoso CL. Effectiveness of hand-cleansing agents for removing methicillin-resistant *Staphylococcus aureus* from contaminated hands. *Infect Control Hosp Epidemiol* 2001;22:105-8.
114. Kampf G, Kramer A. Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs. *Clin Microbiol Rev* 2004;17:863-93, table of contents.
115. McLure AR, Gordon J. In-vitro evaluation of povidone-iodine and chlorhexidine against methicillin-resistant *Staphylococcus aureus*. *J Hosp Infect* 1992;21:291-9.
116. Doudoulakakis A, Spiliopoulou I, Spyridis N, et al. Emergence of a *Staphylococcus aureus* Clone Resistant to Mupirocin and Fusidic Acid Carrying Exotoxin Genes and Causing Mainly Skin Infections. *J Clin Microbiol* 2017;55:2529-37.
117. Duran N, Temiz M, Duran GG, Eryilmaz N, Jenedi K. Relationship between the resistance genes to quaternary ammonium compounds and antibiotic resistance in staphylococci isolated from surgical site infections. *Med Sci Monit* 2014;20:544-50.